Rocket Pharmaceuticals
RCKT
34 hedge funds and large institutions have $32.1M invested in Rocket Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 11 closing their positions.
352% more call options, than puts
Call options by funds: $104K | Put options by funds: $23K
130% more capital inflows, than outflows
Capital inflows: $12M | Capital outflows: $5.21M
7.86% more ownership
Funds ownership: 37.29% → 45.14% (+7.9%)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
3% less funds holding
Funds holding: 35 → 34 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
+$3.22M |
| 2 |
Boxer Capital
San Diego,
California
|
+$2.48M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.42M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.24M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$896K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pura Vida Investments
New York
|
-$2.04M |
| 2 |
GSA Capital Partners
London,
United Kingdom
|
-$877K |
| 3 |
Jennison Associates
New York
|
-$471K |
| 4 |
SAM
Senzar Asset Management
New York
|
-$359K |
| 5 |
Millennium Management
New York
|
-$359K |
RCKT Hedge Fund Activity: Q4 2017 in Review
34 of the 4,420 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q4 2017, worth a combined $32.1M — up 79% from $17.9M a quarter earlier.
Fund positioning in RCKT was balanced in Q4 2017: 11 funds opened new positions, 11 closed out, 9 added to existing stakes and 9 trimmed.
The largest buyer was Ghost Tree Capital, opening a new position worth an estimated $3.22M. The largest seller was Pura Vida Investments, exiting entirely with an estimated $2.04M sold.
- 34 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q4 2017, down from 35 in Q3 2017.
- Funds reported $32.1M of Rocket Pharmaceuticals stock for Q4 2017, up 79% quarter-over-quarter.
- 11 funds opened new Rocket Pharmaceuticals positions in Q4 2017 and 11 closed out, a net change of 0 holders.
- The largest Rocket Pharmaceuticals buyer in Q4 2017 was Ghost Tree Capital, an estimated $3.22M added.
- The largest Rocket Pharmaceuticals seller in Q4 2017 was Pura Vida Investments, an estimated $2.04M sold.
Based on aggregated 13F filings for Q4 2017.